ketanserin has been researched along with Diseases, Metabolic in 1 studies
Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.
ketanserin : A member of the class of quinazolines that is quinazoline-2,4(1H,3H)-dione which is substituted at position 3 by a 2-[4-(p-fluorobenzoyl)piperidin-1-yl]ethyl group.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Oudemans-van Straaten, HM | 1 |
| Jansen, PG | 1 |
| Velthuis, H | 1 |
| Stoutenbeek, CP | 1 |
| Zandstra, DF | 1 |
| Deventer, SJ | 1 |
| Sturk, A | 1 |
| Wildevuur, CR | 1 |
| Eijsman, L | 1 |
1 trial available for ketanserin and Diseases, Metabolic
| Article | Year |
|---|---|
Endotoxaemia and postoperative hypermetabolism in coronary artery bypass surgery: the role of ketanserin.
Topics: Aged; Cardiopulmonary Bypass; Coronary Artery Bypass; Double-Blind Method; Endotoxins; Hemodynamics; | 1996 |